Payers Seek Missing Link Between Diagnostic Tests And Clinical Outcomes
Personalized medicine remains a worthy goal, but for payers the evidence just isn't there yet to support reimbursement of much diagnostic testing, the Tufts Center for the Study of Drug Development concludes in its July/August Impact Report.
You may also be interested in...
FDA approved Pfizer’s lung cancer drug for patients positive for the gene translocation – but review documents show that agency reviewers focused on the efficacy seen in the few ALK-negative patients in the pivotal trial, and want Pfizer to follow up on that signal post-marketing. Regulatory expectations for disproving effect in the non-selected population will be an important issue as more personalized medicines reach the agency.
As personalized medicine shifts from theory to practice, concerns are mounting about whether the evidence behind many biomarkers is sufficient to make pharmacogenomic testing worthwhile – suggesting sponsors should pay careful attention to providing evidence to support use of companion diagnostics.